Leerink Partners Maintains Outperform on AnaptysBio, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Positive 89.7%

Neg 0% Neu 0% Pos 89.7%

Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $66 to $85.